Back

Advancing precision medicine in the Cardiac Intensive Care Unit using universal whole-genome sequencing

Kierulf, G.; Emmerson, M.; Krautscheid, P.; Bleyl, S.; Tristani-Firouzi, M.; Sawyer, B.

2026-05-14 genetic and genomic medicine
10.64898/2026.05.11.26352916 medRxiv
Show abstract

Congenital heart defects (CHD) are a common congenital anomaly and a leading cause of neonatal mortality. Even in ostensibly isolated cases, genetic testing can reveal monogenic causes of isolated CHD or identify syndromic conditions before additional features become clinically apparent. A timely and accurate genetic diagnosis can inform medical management and surveillance, reduce the need for unnecessary investigations, and offer families valuable information about prognosis, recurrence risk, and anticipatory guidance. In September of 2023, Primary Childrens Hospital introduced a universal genetic testing protocol that implemented whole genome sequencing for all neonates admitted to the cardiac intensive care unit (CICU) undergoing cardiac surgery before 30 days of life, with the goal of increasing the number of patients who receive a timely genetic diagnosis and improving clinical care. This is a retrospective chart review of patients who underwent whole genome sequencing (WGS) under the new universal genetic testing protocol at Primary Childrens Hospital from its initiation in September 2023 to February 2026. Over the study period, 217 neonates with CHD participated in the universal WGS protocol. Of these patients, 23 (10.6%) received a genetic diagnosis that was causative of their CHD, of which 11 patients (48%) had no major extracardiac features at the time testing was ordered. Twenty patients were diagnosed with a syndromic condition, and three patients were diagnosed with a non-syndromic condition. All of these patients received additional referrals to specialists following their new diagnosis, and six families used results to inform decisions regarding continuation of care. An additional 19 patients (8.8%) received WGS results that were clinically relevant but non-diagnostic for their CHD, including partial diagnoses, secondary findings, and carrier status. In total, 19.4% of patients (n=42) had clinically relevant variants identified on their WGS.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Genetics in Medicine
69 papers in training set
Top 0.1%
37.8%
2
Circulation: Genomic and Precision Medicine
42 papers in training set
Top 0.2%
10.1%
3
The American Journal of Human Genetics
206 papers in training set
Top 0.6%
7.2%
50% of probability mass above
4
Circulation
66 papers in training set
Top 0.6%
6.3%
5
Genome Medicine
154 papers in training set
Top 2%
4.2%
6
Nature Medicine
117 papers in training set
Top 2%
2.1%
7
JAMA
17 papers in training set
Top 0.1%
1.9%
8
European Journal of Human Genetics
49 papers in training set
Top 0.5%
1.9%
9
The Journal of Pediatrics
15 papers in training set
Top 0.3%
1.8%
10
Trials
25 papers in training set
Top 0.8%
1.7%
11
New England Journal of Medicine
50 papers in training set
Top 0.5%
1.5%
12
Nature Communications
4913 papers in training set
Top 55%
1.3%
13
Human Genetics
25 papers in training set
Top 0.2%
1.3%
14
eLife
5422 papers in training set
Top 47%
1.3%
15
npj Genomic Medicine
33 papers in training set
Top 0.6%
1.2%
16
Journal of the American Heart Association
119 papers in training set
Top 3%
1.1%
17
Journal of the American College of Cardiology
12 papers in training set
Top 0.6%
0.8%
18
Med
38 papers in training set
Top 0.8%
0.7%
19
Journal of the American Medical Informatics Association
61 papers in training set
Top 2%
0.7%
20
Nature Genetics
240 papers in training set
Top 7%
0.7%
21
Genetics in Medicine Open
10 papers in training set
Top 0.1%
0.6%